The past year has been the most important in Emergent BioSolutions’ history. We’ve had the honor of helping our country address Covid-19, manufacturing vaccines in a way few companies can. Deploying longstanding pandemic preparedness capabilities to shorten timelines and ramp up large-scale manufacturing, we can now make more than a billion doses of Covid-19 vaccine a year.
{iframe}https://www.nytimes.com/2021/03/13/opinion/letters/emergent-biosolutions-vaccine.html{/iframe}